REGN5458 Shows Promising ORR and Safety in Relapsed/Refractory Myeloma
Jeffrey Zonder, MD, discusses his presentation at the 2021 ASH Annual Meeting on the impact of the phase 1/2 study utilizing REGN5458 in multiple myeloma.
Related Articles
Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Glofitamab Plus Chemotherapy Meets OS Primary End Point in Relapsed/Refractory DLBCL
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups
Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.
Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
NICE Recommends Tisagenlecleucel for Pediatric R/R B-ALL
The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.
Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Insider Insights: Unveiling Takeaways from AACR 2024
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer
A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.
Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial
Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with…